Beta Bionics reported revenue of $44.7 million and a net loss of $36.6 million for the nine months ending in September 2024, with an installed customer base of 11,214 people.
Revenue Amount
$44,700,000
Company Description
Beta Bionics is a developer of an automated insulin delivery system, specifically the iLet Bionic Pancreas, which automates insulin dosing without any mealtime carb counting.